Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope you had a peaceful holiday. Back to biotech, we discuss the tough job market, delight in some exciting early developments in CAR-T and CRISPR, and see further validation for the blockbuster anti-inflammatory drug Dupixent.
The biotech job market is not in good shape
If you’re in the market for a job in biotech right now, good luck. The industry experienced a heady “sugar high” in 2021, when a strong candidate might field multiple offers at any given time. But the subsequent industry crash has made it difficult for both public and private companies to raise money. Hundreds of companies have downsized, merged, or simply gone out of business. And bioscience job postings have dropped from about 19,000 in February 2022 to 10,000 in October 2023.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect